Valneva assumes responsibility for the delivery of the chikungunya vaccine in Asia.[1] The company has entered into an exclusive licensing agreement with the Serum Institute of India (SII), the world's largest vaccine manufacturer by number of doses.[1] Under the agreement, there will be a transfer of vaccine production technology and Valneva will supply SII with the vaccine substance, while SII will complete the production.[1] SII will be responsible for obtaining and maintaining regulatory approvals in India and other Asian countries.[1] Commercialization will take place on a profit-sharing model with single-digit million milestone payments to Valneva for technology transfer and regulatory approvals.[1] The agreement includes a commitment to equal access to SII-produced vaccine in the region and a safety stock of up to 100,000 doses available to CEPI to respond to future outbreaks.[1] The agreement was announced on 19 December 2024 in Saint-Herblain and Pune.[1]